Moderna (NASDAQ:MRNA – Get Free Report) had its target price raised by Morgan Stanley from $95.00 to $200.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley‘s price target indicates a potential downside of 7.09% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Loop Capital set a $135.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and increased their target price for the company from $40.00 to $81.00 in a report on Thursday, September 3rd. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Friday, August 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $305.00 target price (up from $230.00) on shares of Moderna in a research report on Monday, November 9th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $119.00.
Read Our Latest Stock Report on MRNA
Moderna Stock Down 3.6%
Moderna stock opened at $215.27 on Tuesday. The firm’s 50 day simple moving average is $203.06 and its 200-day simple moving average is $97.26. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $280.80.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm’s revenue was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.51) earnings per share. Analysts anticipate that Moderna will post -5.14 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, President Stephen Hoge sold 39,145 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the sale, the president directly owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Ethic Inc. raised its position in Moderna by 23.6% in the third quarter. Ethic Inc. now owns 19,394 shares of the company’s stock worth $3,735,000 after purchasing an additional 3,700 shares in the last quarter. Merck & Co. Inc. bought a new position in Moderna during the second quarter worth about $161,642,545. Bank of New York Mellon Corp acquired a new stake in Moderna during the second quarter valued at approximately $119,168,000. Contravisory Investment Management Inc. boosted its holdings in Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after purchasing an additional 22,590 shares in the last quarter. Finally, TD Waterhouse Canada Inc. boosted its holdings in Moderna by 2,042.6% during the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after purchasing an additional 69,203 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Moderna
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
